Abstract:Objective This study aims to explore the impact of ADME on the Oral Bioavailability (OB) of drugs and to construct a machine learning model for OB prediction. The model is then applied to predict the OB of modified berberine and atenolol molecules to obtain structures with higher OB. Methods Initially, a drug OB database was established, and corresponding ADME characteristics were obtained. The relationship between ADME and OB was analyzed using machine learning, with Morgan fingerprints serving as molecular descriptors. Compounds from the database were input into Random Forest, XGBoost, CatBoost, and LightGBM machine learning models to train the OB 7prediction model and evaluate its performance. Subsequently, berberine and atenolol were modified using Chemdraw software with ten different substituents for mono-substitution, and chlorine atoms for a full range of double substitutions. The modified molecular structures were converted into the same format as the training set for OB prediction. The predicted OB values of the modified structures of berberine and atenolol were compared. Results An OB database of 386 drugs was obtained. It was found that smaller molecular weight and a higher number of rotatable bonds (ten or less) could potentially lead to higher OB. The four machine learning models were evaluated using MSE, R2 score, MAE, and MFE as metrics, with Random Forest performing the best. The models' predictions for the test set were particularly accurate when OB ranged from 30% to 90%. After mono-substitution and double substitution of berberine and atenolol, the OB of both drugs was significantly improved. Conclusions This study found that some ADME properties of molecules do not have an absolute impact on OB. The database played a decisive role in the process of the machine learning OB prediction model, and the performance of the model was evaluated based on predictions within a range of strong generalization ability. In most cases, mono-substitution and double substitution were beneficial for enhancing the OB of berberine and atenolol. In summary, this study successfully constructed a machine learning regression prediction model that can accurately predict drug OB, which can guide drug design to achieve higher OB to some extent.

Advances in Computationally Modeling Human Oral Bioavailability.

Recent Advances On In Silico Adme Modeling

Computational modeling of human oral bioavailability: what will be next?

Recent developments of in silico predictions of oral bioavailability.

Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap.

A Novel Chemometric Method for the Prediction of Human Oral Bioavailability

ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints.

ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules?

In silico ADME-Tox modeling: progress and prospects

In Silicoadme/t Modelling for Rational Drug Design

Structure-ADME relationship: still a long way to go?

ADME Evaluation in Drug Discovery. Part 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property‐Based Rules?

Structure – ADME Relationship: Still a Long Way to Go?

In Silico ADME Modeling 3: Computational Models to Predict Human Intestinal Absorption Using Sphere Exclusion and kNN QSAR Methods

Advances in Modeling Approaches for Oral Drug Delivery: Artificial Intelligence, Physiologically-Based Pharmacokinetics, and First-Principles Models

Construction of an Oral Bioavailability Prediction Model Based on Machine Learning for Evaluating Molecular Modifications

In Silico Admet Prediction : Recent Advances, Current Challenges and Future Trends

Research on prediction of human oral bioavailability of drugs based on improved deep forest

Recent advances in computational prediction of drug absorption and permeability in drug discovery.

Predicting human intestinal absorption with modified random forest approach: a comprehensive evaluation of molecular representation, unbalanced data, and applicability domain issues

Validating ADME QSAR Models Using Marketed Drugs